Chronic myeloid leukemia (CML) is a malignant neoplasm characterized by the clonal proliferation of hematopoietic stem cells driven by the breakpoint cluster region–Abelson (BCR::ABL1) fusion gene (Alves et al., 2021; Deininger et al., 2020; Garcia-Ferrer et al., 2019), with more than 90% of patients exhibiting Philadelphia chromosome (Ph) abnormalities (Tian et al., 2018). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.